recently also identified EGR1 as a regulator of genes including GAS1, CD59, CXCR7, and RAMP3 in NKTCL, which is often present in localized and low-risk patients and which may thus present as a tool useful for stratifying NKTCL patients who are likely to perform better (68). This evidence concerns the gene GAS1 and extranodal nasal NK/T cell lymphoma.